A decade after the Human Genome Project's completion, scientists have an improved understanding of nearly 5,000 diseases but personalized treatments for a relative handful. Ten years ago, four FDA-approved labels included information on genetics, and now the figure exceeds 100. Genes operate in networks, making development of targeted therapies elusive, says Eric Schadt, chairman of genetics and genomic sciences at Mount Sinai Icahn School of Medicine. "We keep learning how much we really don't know and how much further we need to go," Schadt said.

Full Story:
HealthDay News

Related Summaries